NIH: Pharmacokinetic-Profile Extending Technology Now Available

The National Institutes of Health has announced the commercial availability of a platform technology that extends the pharmacokinetic properties of certain classes of drugs.

According to a notice, the licensing offer benefits early-stage drugs and features other advantages such as eliminating renal clearance.

It has applicability to cancer drugs, diabetes drugs and central nervous system drugs.